The Zhitong Finance App learned that Citibank released a research report saying that Rongchang Biotech (09995.HK)'s revenue in the first half of the year increased by 433% year-on-year, turning a loss into profit and earning 4.66 billion yuan. Management said that the net loss for the first half of the year after excluding BD revenue was about RMB 26 million, and it is expected that after excluding BD revenue, balance of income and expenditure can be achieved in the 2026 fiscal year. The target price was raised from HK$105 to HK$127.7, and the “Buy/High Risk” rating was renewed.

The Zhitong Finance App learned that Citibank released a research report saying that Rongchang Biotech (09995.HK)'s revenue in the first half of the year increased by 433% year-on-year, turning a loss into profit and earning 4.66 billion yuan. Management said that the net loss for the first half of the year after excluding BD revenue was about RMB 26 million, and it is expected that after excluding BD revenue, balance of income and expenditure can be achieved in the 2026 fiscal year. The target price was raised from HK$105 to HK$127.7, and the “Buy/High Risk” rating was renewed.